152
Participants
Start Date
January 31, 2008
Primary Completion Date
April 30, 2009
Study Completion Date
April 30, 2009
adalimumab
Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
New York University School of Medicine, New York
Mount Sinai School of Medicine, New York
Montifiore Medical Center, The Bronx
Paddington Testing Co., Philadelphia
Virginia Clinical Research, Inc., Norfolk
Radiant Research, Greer
Peachtree Dermatology Associates, Atlanta
Florida Academic Dermatology Centers, Miami
Total Skin and Beauty Dermatology Centers, Birmingham
Dawes Fretzin Clinical Research Group, Indianapolis
Dermatology Research of Arkansas, Little Rock
Dermatology Treatment & Research Center, PA Research, Dallas
Baylor Research Institute, Dallas
Center for Clinical Studies, Houston
Therapeutics Clinical Research, San Diego
Dermatology Associates, Seattle
ORA Clinical Research and Development, Andover
Clinical Partners, Johnston
Kirk Barber Research, Calgary
Stratica Medical, Edmonton
Eastern Canada Cutaneous Research Associates, Halifax
Dermatrials Research, Hamilton
K.Papp Clinical Research Inc, Waterloo
Siena Medical Research, Montreal
Centre de Rescherche Dermatologique Du Quebec Metropolitain, Québec
Lead Sponsor
Abbott
INDUSTRY